Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 32 articles:
HTML format



Single Articles


    December 2023
  1. HE W, Zeng S, Xu C
    Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2301920. doi: 10.1200/JCO.23.01920.
    PubMed    


    November 2023
  2. CATHOMAS R, Rothschild SI, Hayoz S, Bubendorf L, et al
    Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
    J Clin Oncol. 2023;41:5131-5139.
    PubMed     Abstract available


    October 2023
  3. KAMAT AM, Apolo AB, Babjuk M, Bivalacqua TJ, et al
    Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
    J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
    PubMed     Abstract available


    September 2023
  4. SIEFKER-RADTKE AO, Cauley D, Alhalabi O
    Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:4084-4086.
    PubMed    


    August 2023
  5. VON DER MAASE H, Hansen SW, Roberts JT, Dogliotti L, et al
    Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
    J Clin Oncol. 2023;41:3881-3890.
    PubMed     Abstract available


  6. SMALL EJ
    Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
    J Clin Oncol. 2023;41:3879-3880.
    PubMed    


  7. STEIN JP, Lieskovsky G, Cote R, Groshen S, et al
    Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
    J Clin Oncol. 2023;41:3772-3781.
    PubMed     Abstract available



  8. JCO Flashback: Long-Term Outcomes of Radical Cystectomy in Patients With Invasive Bladder Cancer (2001).
    J Clin Oncol. 2023;41:3771.
    PubMed    


  9. BOSL GJ
    Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer.
    J Clin Oncol. 2023;41:3769-3770.
    PubMed    


    July 2023
  10. SWINTON M, Mariam NBG, Tan JL, Murphy K, et al
    Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Jul 21:JCO2300725. doi: 10.1200/JCO.23.00725.
    PubMed     Abstract available


  11. POWLES T, Park SH, Caserta C, Valderrama BP, et al
    Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up.
    J Clin Oncol. 2023;41:3486-3492.
    PubMed     Abstract available


    June 2023
  12. SARFATY M, Golkaram M, Funt SA, Al-Ahmadie H, et al
    Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
    J Clin Oncol. 2023;41:3225-3235.
    PubMed     Abstract available


    March 2023
  13. COLEMAN JA, Yip W, Wong NC, Sjoberg DD, et al
    Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
    J Clin Oncol. 2023;41:1618-1625.
    PubMed     Abstract available


    January 2023

  14. Erratum: DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    J Clin Oncol. 2023 Jan 25:JCO2202889. doi: 10.1200/JCO.22.02889.
    PubMed    


  15. STERNBERG CN, Petrylak DP, Bellmunt J, Nishiyama H, et al
    FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
    J Clin Oncol. 2023;41:629-639.
    PubMed     Abstract available


  16. SADEGHI S, Quinn D, Dorff T, Pal S, et al
    EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:640-650.
    PubMed     Abstract available


  17. PLIMACK ER, Zibelman MR
    Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?
    J Clin Oncol. 2023;41:7-10.
    PubMed     Abstract available


  18. CRABB SJ, Hussain S, Soulis E, Hinsley S, et al
    A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:54-64.
    PubMed     Abstract available


  19. ROSENBERG JE, Park SH, Kozlov V, Dao TV, et al
    Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    J Clin Oncol. 2023;41:43-53.
    PubMed     Abstract available


    November 2022
  20. KIM SH, Lerner SP
    Risk Stratification of Nonmuscle Invasive Bladder Cancer and Innovative Approaches to Management of Ta Low-Grade Tumors.
    J Clin Oncol. 2022 Nov 30:JCO2202104. doi: 10.1200/JCO.22.02104.
    PubMed    


    October 2022
  21. LINDGREN MS, Hansen E, Azawi N, Nielsen AM, et al
    DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    J Clin Oncol. 2022 Oct 12:JCO2200470. doi: 10.1200/JCO.22.00470.
    PubMed     Abstract available


    August 2022
  22. ZHANG S
    Neoadjuvant Programmed Cell Death Protein 1 and Chemotherapy in Combination in Muscle-Invasive Urothelial Cancer: Promising, But Not Deserving to Try Further.
    J Clin Oncol. 2022;40:2656.
    PubMed     Abstract available


    July 2022
  23. GRIMM MO, Schmitz-Drager BJ, Zimmermann U, Grun CB, et al
    Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
    J Clin Oncol. 2022;40:2128-2137.
    PubMed     Abstract available


    June 2022
  24. ZENG S, Zhang Z, Xu C
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial.
    J Clin Oncol. 2022 Jun 15:JCO2200669. doi: 10.1200/JCO.22.00669.
    PubMed    


    May 2022
  25. OWENS-WALTON J, Williams C, Rompre-Brodeur A, Pinto PA, et al
    Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology.
    J Clin Oncol. 2022;40:1583-1589.
    PubMed     Abstract available


    April 2022
  26. SONPAVDE GP, Mouw KW, Mossanen M
    Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.
    J Clin Oncol. 2022;40:1275-1280.
    PubMed     Abstract available


    March 2022
  27. PFISTER C, Gravis G, Flechon A, Chevreau C, et al
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
    J Clin Oncol. 2022 Mar 7:JCO2102051. doi: 10.1200/JCO.21.02051.
    PubMed     Abstract available


    January 2022
  28. FUNT SA, Lattanzi M, Whiting K, Al-Ahmadie H, et al
    Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    J Clin Oncol. 2022 Jan 28:JCO2101485. doi: 10.1200/JCO.21.01485.
    PubMed     Abstract available


    October 2021
  29. POWLES T, Petrylak DP, Rosenberg JE
    Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2021;39:3411-3412.
    PubMed    


    August 2021
  30. ROSE TL, Harrison MR, Deal AM, Ramalingam S, et al
    Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2021 Aug 24:JCO2101003. doi: 10.1200/JCO.21.01003.
    PubMed     Abstract available


  31. ROSENBERG JE, Ballman KA, Halabi S, Atherton PJ, et al
    Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
    J Clin Oncol. 2021;39:2486-2496.
    PubMed     Abstract available


    December 2020
  32. CATTO JWF, Gordon K, Collinson M, Poad H, et al
    Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
    J Clin Oncol. 2020 Dec 17:JCO2001665. doi: 10.1200/JCO.20.01665.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.